CalciMedica (NASDAQ:CALC – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
CalciMedica Stock Up 3.5 %
CALC stock opened at $2.08 on Tuesday. CalciMedica has a 52-week low of $1.83 and a 52-week high of $6.27. The business has a fifty day moving average of $2.47 and a two-hundred day moving average of $3.22. The stock has a market cap of $28.04 million, a price-to-earnings ratio of -1.93 and a beta of 1.20.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research report on Tuesday, March 4th.
CalciMedica Company Profile
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- What Are Dividend Contenders? Investing in Dividend Contenders
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Options Trading – Understanding Strike Price
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Canada Bond Market Holiday: How to Invest and Trade
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
